Please wait

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Urban Michael J. (Last) (First) (Middle) C/O WEREWOLF THERAPEUTICS, INC. 200 TALCOTT AVENUE, 2ND FLOOR (Street) WATERTOWN MA 02472 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/13/2026	3. Issuer Name and Ticker or Trading Symbol Werewolf Therapeutics, Inc. [ HOWL ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) VP of Finance & Corp. Contr.	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,284	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	05/31/2033	Common Stock	52,500	$3.65	D
Stock Option (right to buy)	(2)	01/01/2034	Common Stock	29,365	$4.64	D
Stock Option (right to buy)	(3)	12/18/2034	Common Stock	10,000	$1.57	D
Stock Option (right to buy)	(4)	01/01/2035	Common Stock	54,800	$1.56	D

Explanation of Responses:

1. The option was granted on June 1, 2023. The shares underlying the option vested as to 25% on May 15, 2024, and the remainder vest in substantially equal monthly installments thereafter through May 15, 2027.

2. The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in substantially equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028.

3. The option was granted on December 19, 2024, and is fully vested.

4. The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in substantially equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Jonathan Owen, Attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.